Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment

References

1. 1.↵
   1. Thal LJ,
   2. Kantarci K,
   3. Reiman EM,
   4. et al

   . The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:6–15

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Petersen RC,
   2. Stevens JC,
   3. Ganguli M,
   4. et al

   . Practice parameter: early detection of dementia—mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–42

   Abstract/FREE Full Text
3. 3.↵
   1. Chetelat G,
   2. Desgranges B,
   3. de la Sayette V,
   4. et al

   . Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374–77

   Abstract/FREE Full Text
4. 4.↵
   1. De Santi S,
   2. de Leon MJ,
   3. Rusinek H,
   4. et al

   . Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–39

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Drzezga A,
   2. Lautenschlager N,
   3. Siebner H,
   4. et al

   . Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104–13

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Minoshima S,
   2. Giordani B,
   3. Berent S,
   4. et al

   . Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85–94

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Nestor PJ,
   2. Fryer TD,
   3. Smielewski P,
   4. et al

   . Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343–51

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Mosconi L,
   2. Brys M,
   3. Glodzik-Sobanska L,
   4. et al

   . Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007;42:129–38

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Kim EJ,
   2. Cho SS,
   3. Jeong Y,
   4. et al

   . Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005;128:1790–801

   Abstract/FREE Full Text
10. 10.↵
    1. Sakamoto S,
    2. Ishii K,
    3. Sasaki M,
    4. et al

    . Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 2002;200:27–32

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Matsunari I,
    2. Samuraki M,
    3. Chen WP,
    4. et al

    . Comparison of 18F-FDG-PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med 2007;48:1961–70

    Abstract/FREE Full Text
12. 12.↵
    1. Petersen RC,
    2. Kokmen E,
    3. Tangalos E,
    4. et al

    . Mayo Clinic Alzheimer's Disease Patient Registry. Aging (Milano) 1990;2:408–15

    PubMed
13. 13.↵
    1. Kantarci K,
    2. Petersen RC,
    3. Przybelski SA,
    4. et al

    . Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 2008;65:1621–28

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Murray ME,
    2. Shiung MM,
    3. Weigand SD,
    4. et al

    . Mayo MRI visual grading scale: validation studies. In: Proceedings of the 37th Annual Meeting of the Society for Neuroscience,San Diego, California. November 3–7, 2007
15. 15.↵
    1. Tzourio-Mazoyer N,
    2. Landeau B,
    3. Papathanassiou D,
    4. et al

    . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273–89

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Hoffman JM,
    2. Welsh-Bohmer KA,
    3. Hanson M,
    4. et al

    . FDG-PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920–28

    Abstract/FREE Full Text
17. 17.↵
    1. Jagust W,
    2. Reed B,
    3. Mungas D,
    4. et al

    . What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69:871–77

    Abstract/FREE Full Text
18. 18.↵
    1. Silverman DH,
    2. Small GW,
    3. Chang CY,
    4. et al

    . Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120–27

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Vemuri P,
    2. Whitwell JL,
    3. Kantarci K,
    4. et al

    . Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559–67. Epub 2008 May 20

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Ashburner J,
    2. Friston KJ

    . Unified segmentation. Neuroimage 2005;26:839–51

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Meltzer CC,
    2. Kinahan PE,
    3. Greer PJ,
    4. et al

    . Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40:2053–65

    Abstract/FREE Full Text
22. 22.↵
    1. Sun FT,
    2. Schriber RA,
    3. Greenia JM,
    4. et al

    . Automated template-based PET region of interest analyses in the aging brain. Neuroimage 2007;34:608–17

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Vemuri P,
    2. Gunter JL,
    3. Senjem ML,
    4. et al

    . Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008;39:1186–97

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Roberts RO,
    2. Geda YE,
    3. Knopman DS,
    4. et al

    . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58–69. Epub 2008 Feb 7

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Anchisi D,
    2. Borroni B,
    3. Franceschi M,
    4. et al

    . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728–33

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Bigio EH,
    2. Hynan LS,
    3. Sontag E,
    4. et al

    . Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 2002;28:218–27

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Bennett DA,
    2. Wilson RS,
    3. Schneider JA,
    4. et al

    . Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205

    Abstract/FREE Full Text
28. 28.↵
    1. Jicha GA,
    2. Parisi JE,
    3. Dickson DW,
    4. et al

    . Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63:674–81

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Morris JC,
    2. Price AL

    . Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101–18

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Petersen RC,
    2. Parisi JE,
    3. Dickson DW,
    4. et al

    . Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63:665–72

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Storandt M,
    2. Grant EA,
    3. Miller JP,
    4. et al

    . Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006;67:467–73

    Abstract/FREE Full Text
32. 32.↵
    1. Schneider JA,
    2. Arvanitakis Z,
    3. Bang W,
    4. et al

    . Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–204

    Abstract/FREE Full Text
33. 33.↵
    1. Seo SW,
    2. Cho SS,
    3. Park A,
    4. et al

    . Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging 2009;19:213–9. Epub 2009 Nov 3

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Savva GM,
    2. Wharton SB,
    3. Ince PG,
    4. et al

    . Age, neuropathology, and dementia. N Engl J Med 2009;360:2302–09

    CrossRefPubMedWeb of Science